Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Winston

Showing results (41-50 of 241) with videos related to

Pageof 25
Sort By:
Current HIV/AIDS Reports|June 1, 2026
Central Nervous System HIV Persistence and Clinical Consequences During Suppressive ARTKathryn B Holroyd, Serena Spudich, Alan Winston, et al.
The Open AIDS Journal|March 11, 2009
High treatment success rates when switching to once daily nevirapine containing antiretroviral therapyAndrew Benzie, Brett Marett, Nicola E Mackie, et al.
International Journal of STD & AIDS|September 6, 2007
Pharyngeal gonorrhoea - is dual therapy the way forward?Leena Sathia, Ben Ellis, Stuart Phillip, et al.
Sexually Transmitted Infections|January 22, 2020
Cerebrospinal fluid TPPA titres in the diagnosis of neurosyphilisFareed Shiva, David Goldmeier, Paul Lane, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 2007
Polymorphisms at position 245 of HIV reverse transcriptase do not accurately predict the presence of human leukocyte antigen B*5701Laura J Waters, Nicola E Mackie, Anton Pozniak, et al.
Current Drug Safety|August 12, 2008
Host pharmacogenetics in the treatment of HIV and cancerAlan Winston, Eleftheria Hatzimichael, Vanessa Marvin, et al.
AIDS (London, England)|October 9, 2002
The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patientsAlan Winston, Sundhiya Mandalia, Deenan Pillay, et al.
AIDS (London, England)|October 4, 2012
The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotypeJaime H Vera, Nadia Naous, Nicola Mackie, et al.
AIDS Research and Human Retroviruses|April 21, 2006
Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individualsAlan Winston, Janaki Amin, Gill Hales, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 14, 2018
Self-management Interventions for Pain and Physical Symptoms Among People Living With HIV: A Systematic Review of the EvidenceKennedy Nkhoma, Christine Norton, Caroline Sabin, et al.
Pageof 25

Showing results (41-50 of 241) with videos related to

Sort By:
Pageof 25
Current HIV/AIDS Reports|June 1, 2026
Central Nervous System HIV Persistence and Clinical Consequences During Suppressive ARTKathryn B Holroyd, Serena Spudich, Alan Winston, et al.
The Open AIDS Journal|March 11, 2009
High treatment success rates when switching to once daily nevirapine containing antiretroviral therapyAndrew Benzie, Brett Marett, Nicola E Mackie, et al.
International Journal of STD & AIDS|September 6, 2007
Pharyngeal gonorrhoea - is dual therapy the way forward?Leena Sathia, Ben Ellis, Stuart Phillip, et al.
Sexually Transmitted Infections|January 22, 2020
Cerebrospinal fluid TPPA titres in the diagnosis of neurosyphilisFareed Shiva, David Goldmeier, Paul Lane, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 2007
Polymorphisms at position 245 of HIV reverse transcriptase do not accurately predict the presence of human leukocyte antigen B*5701Laura J Waters, Nicola E Mackie, Anton Pozniak, et al.
Current Drug Safety|August 12, 2008
Host pharmacogenetics in the treatment of HIV and cancerAlan Winston, Eleftheria Hatzimichael, Vanessa Marvin, et al.
AIDS (London, England)|October 9, 2002
The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patientsAlan Winston, Sundhiya Mandalia, Deenan Pillay, et al.
AIDS (London, England)|October 4, 2012
The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotypeJaime H Vera, Nadia Naous, Nicola Mackie, et al.
AIDS Research and Human Retroviruses|April 21, 2006
Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individualsAlan Winston, Janaki Amin, Gill Hales, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 14, 2018
Self-management Interventions for Pain and Physical Symptoms Among People Living With HIV: A Systematic Review of the EvidenceKennedy Nkhoma, Christine Norton, Caroline Sabin, et al.
Pageof 25